Research peptides in the European Union: one definition, twenty-seven enforcers, and a Dutch record

The European Union has one definition of a medicine and twenty-seven authorities to apply it. Directive 2001/83/EC says what a medicinal product is, says that nothing may be sold as one without an authorisation, and says that in cases of doubt medicines law wins. It leaves the deciding, the licensing and the policing to each member state. For research peptides that produces a single rule read through twenty-seven enforcement cultures, and in 2026 two of them wrote the record that matters: the Netherlands, whose health inspectorate tested peptides bought from Dutch webshops, found every one over-strength, and then ordered a seller to stop and fined it when it did not; and Germany, where the doping statute makes possession of a list of peptides a criminal offence whatever the label says. This page sets out the Directive, the three Court of Justice rulings that decide when a peptide is a medicine by function, the Dutch and German systems in depth, the record elsewhere in Europe, the border inside and outside the single market, and where research material stands.

The Directive: one definition, a doubt rule, and two prohibitions

Article 1(2) of Directive 2001/83/EC defines a medicinal product as any substance or combination of substances presented as having properties for treating or preventing disease in human beings, or any substance or combination of substances which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis. Presentation and function: the same two limbs the United Kingdom kept after leaving. Article 2(2) adds the rule for the borderline: where a product may fall within the definition of a 'medicinal product' and within the definition of a product covered by other Community legislation the provisions of this Directive shall apply. A research chemical that could be a medicine is handled as a medicine.

Two prohibitions follow. Article 6(1): No medicinal product may be placed on the market of a Member State unless a marketing authorisation has been issued by the competent authorities of that Member State or by the Union. Article 87(1): Member States shall prohibit any advertising of a medicinal product in respect of which a marketing authorization has not been granted. No research peptide holds a marketing authorisation anywhere in the Union. If it is a medicine, it may be neither sold nor advertised, in any member state.

The Court of Justice: when a substance with no claims is a medicine

Three judgments supply the method every national authority uses. In Van Bennekom (1983) the Court held that a product is presented as a medicine whenever an averagely well-informed consumer gains the impression, even by implication, that it has medicinal properties; presentation is read from the whole product, packaging and format included. In HLH Warenvertriebs (2005) the Court held that whether a product is a medicine by function must be decided case by case, taking account of its composition, its pharmacological properties as far as science can establish them, the manner in which it is used, the extent of its distribution, its familiarity to consumers and the risks its use may entail. And in Hecht-Pharma (2009) the Court drew the floor: a product is not a medicine by function if, in its composition and as used, it is incapable of appreciably restoring, correcting or modifying physiological functions. A slight effect is not enough. An appreciable one, at the amount sold, is.

For a research peptide with no claims attached, the function limb is where the question lives, exactly as in the United Kingdom. The pharmacology of a peptide at the quantity in a vial, the way the vial is used, how widely it is sold and how well the public knows it are all factors, and for a peptide that is widely known for human use and sold in a single-use format most of them point toward medicine by function. A milligram quantity of lyophilized powder sold to a laboratory with reference data points the other way. No national authority has published a determination for a research-labeled peptide sold without claims, and the Court's method does not produce one in the abstract. It produces one product at a time.

The Netherlands: tested, ordered, fined

The Geneesmiddelenwet copies the Directive with one sharpening. Article 1(1)(b) defines a medicine as a substance intended to be administered or applied to, or presented in any way as suitable for curing or preventing disease, making a diagnosis, or restoring, improving or otherwise modifying physiological functions in humans through a pharmacological, immunological or metabolic effect. "Presented in any way" is the Dutch legislature's gloss on Van Bennekom, and the Inspectie Gezondheidszorg en Jeugd, the health inspectorate, applies it.

In March 2026 the investigative program Pointer bought five peptides from Dutch webshops and had the Leiden University Medical Center analyze them. Every one contained more active substance than its label stated, one by a factor of fourteen. Three of the five contained substances the seller had not declared. Two of the bacteriostatic water vials supplied with them lacked the preservative that makes bacteriostatic water bacteriostatic. The products were labeled "not for human use" and sold as research chemicals. The director of the Dutch institute for responsible medicine use told the program that the sale of these peptides has nothing to do with research. The adverse-event center Lareb reported two serious cases, one a person in intensive care with brain, kidney and eye damage after using an investigational obesity peptide bought online.

The inspectorate's response, given to the consumer program Radar on March 2, 2026, was that prescription medicines may be offered only by licensed pharmacies, that describing a product as being for research does not take it outside the law, and that investigations were under way with closures and fines as the possible outcome. The advertising standards foundation added that prescription medicines may not be advertised to the public at all, by sellers or by influencers. On August 24, 2026 the inspectorate ordered a webshop to stop supplying and trading three obesity-medicine peptides, after multiple reports of harm. On August 31 it imposed a penalty order, €10,000 for each day of non-compliance up to €200,000, having found the same products on sale on the seller's two sites on August 20, 21 and 24. The Dutch record is the European Union's first complete sequence on research-labeled peptides: laboratory evidence, public warning, order, penalty.

Germany: medicines law, and a doping law that reaches possession

The Arzneimittelgesetz defines a medicine in § 2(1) in the Directive's terms: substances intended for use in or on the human body and designed as remedies to cure, alleviate or prevent human diseases, or that can be applied to or administered to humans to restore, correct or influence physiological functions through pharmacological, immunological or metabolic action. Section 21 requires an authorisation before a medicine is placed on the market, and § 96 makes placing one on the market without it a criminal offence punishable by up to one year's imprisonment or a fine. The federal institute for drugs and medical devices, BfArM, and the state authorities apply it. No BfArM action naming a research peptide is on the public record, and this page does not claim one.

What makes Germany different is the Anti-Doping-Gesetz of 2015. Section 2(1) prohibits manufacturing, trading in, selling, dispensing or prescribing a doping substance for the purpose of doping in sport. Section 2(3) prohibits acquiring, possessing or bringing into the country a doping substance in not small quantity for that purpose. The substances are listed in an annex that follows the international convention against doping, and the annex names, under growth hormone releasing factors, Sermorelin, Somatorelin, Tesamorelin, mod-GRF, CJC-1295; under secretagogues Anamorelin, Ipamorelin, Lenomorelin, Macimorelin, Ibutamoren, Tabimorelin; under releasing peptides GHRP-2, GHRP-2-Gly, GHRP-6, GHRP-6-Gly, Hexarelin; and thymosin beta-4 with its derivatives including TB-500. BPC-157 is not in the annex. For the peptides that are, Germany is the one European jurisdiction in which possession itself, above a threshold quantity and for a sporting purpose, is a crime, and the research label is no answer to a charge that turns on what the holder meant to do with the vial.

German customs enforce both statutes on the postal stream. In March 2026 the main customs office at Ulm reported checking international mail at a distribution center on Lake Constance and opening eighteen criminal proceedings against recipients, with 4,500 tablets and 250 ampoules of doping agents and 3,000 medicine tablets among the finds, one preparation at 1,778 times its declared strength. The release does not say which substances were in the ampoules. It does show where the German line is drawn: at the parcel, against the recipient.

Elsewhere in Europe

• Switzerland, outside the Union but inside its postal flows, ran a joint action named "Peptide 2026" with Swissmedic, the federal customs office and Swiss Sport Integrity, reported on June 30, 2026. Of 46 shipments of peptide preparations checked, 23 were held: 21 classified as doping substances and two as medicinal products. About 80 percent came from Poland, often falsely declared. The release states that distributing unlicensed medicines, including by dropshipping, is illegal regardless of labels such as "research chemical" or "not for human use".
• Iceland, in the European Economic Area, seized more than 5,000 vials of peptides in Europol's Operation SHIELD VI between April and November 2025. The peptides came from China by post and express courier. Across the thirty participating countries the operation seized medicines valued above €33 million, charged 3,354 people and investigated 43 organised groups.
• Interpol's Operation Pangea XVIII, March 10 to 23, 2026, across 90 countries with Europol and the European Anti-Fraud Office among its partners, reported growing demand for peptides, products that were originally used in research settings and are now widely sold as "research chemicals" or "cosmetic peptides" to avoid detection, with significant seizures in Australia, Ireland and New Zealand.

The Swiss finding that most parcels came from Poland is the detail to hold on to. It means the European research-peptide trade is largely intra-European, and intra-European parcels do not pass customs.

The border, inside and outside the single market

At the Union's external border each member state's customs service applies its own medicines law to arriving parcels, which is how the German and Icelandic seizures were made. Inside the single market there is no customs border, so a peptide shipped from Poland to the Netherlands meets no inspector until the Dutch inspectorate reads the seller's website. The Court of Justice held in DocMorris (2003) that a member state may ban mail-order sale of prescription-only medicines but not of authorised non-prescription ones; a research peptide that is a medicine is an unauthorised one, and its sale by mail is prohibited everywhere by Article 6 before any national rule is reached. The practical consequence is that European enforcement against research peptides happens where the Dutch did it, at the seller, through the website, and not at the parcel.

Chemicals law runs alongside. A peptide placed on the market as a substance falls under REACH and the CLP regulation on classification, labeling and safety data sheets. Meeting those obligations is the clearest statement a supplier can make, under European law, that it is selling a chemical. It does not decide the medicines question, because Article 2(2) resolves doubt the other way, but it is evidence of what the product is presented as.

What the medicines agency expects of a peptide

The European Medicines Agency adopted its guideline on the development and manufacture of synthetic peptides, reference EMA/CHMP/CVMP/QWP/367182/2025, on December 9, 2025, in effect from June 1, 2026. It applies to peptides in authorised medicines and in clinical trials, not to research reagents, and sets out what the agency expects a manufacturer to show about a synthetic peptide: the manufacturing process, its characterization, its specifications and its analytical control. The list is the same one this library's methods series describes for a research certificate of analysis, and the guideline is the clearest European statement of what characterizing a peptide means. A supplier whose certificate reports identity, purity, net content, related substances, counter-ion and water is documenting a research chemical to the standard the Union applies to a medicine's active substance. One that reports a purity figure alone is not.

Where research material stands

Under the Directive a research peptide is a medicine by presentation if anyone presents it as one, and a medicine by function if it appreciably modifies physiological functions as sold and used. The second question is decided product by product, nationally, and no authority has decided it for a research-labeled peptide sold without claims. The Dutch record shows what the authorities act on: webshops selling to the public, products over-strength and contaminated, reports of harm. The German record shows a second line that the research label cannot cross: for the peptides in the doping annex, possession above a threshold for a sporting purpose is a crime, whatever the vial says. No action in any member state has been taken against a laboratory, or against a supplier that made no representation for use in the body.

What is different, and what is the same

• The test is the British test, applied twenty-seven times. Presentation and function, with the Court of Justice's case law binding every authority. The difference from the United Kingdom is the enforcer, not the law.
• Germany criminalizes possession for some peptides. The doping annex names CJC-1295, ipamorelin, the GHRPs, hexarelin and TB-500 but not BPC-157. Nowhere else in this series, except Australia for BPC-157, does holding a vial expose the holder.
• The Netherlands produced the first laboratory evidence. Five products, every one over-strength, three contaminated. That evidence, not the research label, is what moved the inspectorate.
• The research label is rejected in the same words everywhere. The Dutch inspectorate, the Swiss authorities and Interpol each said in 2026 that "research chemical" labeling does not change what the product is.
• Enforcement is at the seller. Because the single market has no internal customs, the parcel is not where European enforcement happens. The website is.

What to watch

• Whether the Dutch inspectorate's order and penalty against one seller become a sequence against several, and whether any is taken to court.
• Whether BfArM or a German state authority publishes an action naming a research peptide, which would be the first.
• Poland, named as the origin of most Swiss seizures, and whether its authorities act on the sellers there.
• Any Court of Justice reference asking whether a research-labeled peptide sold without claims is a medicine by function, which would produce the first Union-wide answer.

Frequently asked questions

Are research peptides legal in the European Union?

The Directive makes a peptide a medicine by presentation if it is presented as having medicinal properties, or by function if it appreciably modifies physiological functions as sold. A medicine without a marketing authorisation may not be sold or advertised in any member state. Whether a research-labeled peptide sold without claims is a medicine by function is decided product by product by national authorities, and none has published such a decision.

Is BPC-157 legal in Germany?

BPC-157 holds no authorisation under the Arzneimittelgesetz, so it may not be sold as a medicine, and placing it on the market as one is an offence. It is not in the Anti-Doping-Gesetz annex, so possession is not caught by that statute; CJC-1295, ipamorelin, the GHRPs and TB-500 are.

Are research peptides legal in the Netherlands?

The inspectorate's position is that prescription medicines may be sold only by licensed pharmacies and that describing a product as being for research does not exempt it. In 2026 it ordered a webshop to stop selling peptides and imposed a penalty of €10,000 per day when it did not.

Does "research chemical" labeling protect a seller in Europe?

The Dutch inspectorate, the Swiss authorities and Interpol each said in 2026 that it does not. Under the Directive, presentation is read from the whole product and doubt is resolved in favour of medicines law.

Can I import peptides into the EU for personal use?

Rules differ by member state. A peptide that is a medicine is an unauthorised one, and national customs may seize it at the external border; Germany opens criminal proceedings against recipients of doping substances. This page describes the law and does not advise anyone to import anything.

Sources & Further Reading

1. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use: Articles 1(2), 2(2), 6(1) and 87(1).
2. Court of Justice of the European Union: Van Bennekom, Case 227/82 (1983); HLH Warenvertriebs and Orthica, Joined Cases C-211/03, C-299/03 and C-316/03 to C-318/03 (2005); Hecht-Pharma, Case C-140/07 (2009); Deutscher Apothekerverband v. DocMorris, Case C-322/01 (2003).
3. Geneesmiddelenwet (Netherlands), Article 1(1)(b); Inspectie Gezondheidszorg en Jeugd, order to an online seller, August 24, 2026, and penalty order, August 31, 2026; Radar (AVROTROS), responses of the IGJ, NVWA, Lareb and Stichting Reclame Code, March 2, 2026; Pointer (KRO-NCRV), investigation with the Leiden University Medical Center, March 30, 2026. The seller's name is omitted by this library's policy.
4. Arzneimittelgesetz (Germany), § 2(1), § 21, § 96; Anti-Doping-Gesetz, § 2(1) and (3) and Anlage; Hauptzollamt Ulm, press release, March 4, 2026.
5. Bundesamt für Zoll und Grenzsicherheit, Swissmedic and Swiss Sport Integrity, "Behördenübergreifende Schwerpunktaktion «Peptide 2026»", June 30, 2026.
6. Iceland Revenue and Customs, "Large quantity of illegal peptides seized in international operation", March 2, 2026, on Europol's Operation SHIELD VI; Interpol, "Global crackdown on illicit pharmaceuticals sees USD 15.5 million in seizures", 2026, on Operation Pangea XVIII.
7. European Medicines Agency, Guideline on the development and manufacture of synthetic peptides, EMA/CHMP/CVMP/QWP/367182/2025, adopted December 9, 2025, in effect June 1, 2026.
8. Regulation (EC) No 1907/2006 (REACH) and Regulation (EC) No 1272/2008 (CLP).

Cosmic Peptides. (2026, November 1). Research peptides in the European Union: one definition, twenty-seven enforcers, and a Dutch record. Cosmic Peptides Research Library. Retrieved November 3, 2026, from https://cosmicpeptides.com/research/compliance/research-peptides-in-the-european-union

@misc{cosmicpeptides_research_compliance_research_peptides_in_the_european_union,
  author       = {{Cosmic Peptides}},
  title        = {Research peptides in the European Union: one definition, twenty-seven enforcers, and a Dutch record},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/research-peptides-in-the-european-union},
  urldate      = {2026-11-03},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Research peptides in the European Union: one definition, twenty-seven enforcers, and a Dutch record
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/compliance/research-peptides-in-the-european-union
Y2  - 2026/11/03
LA  - en
ER  -